Literature DB >> 11834501

Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization.

Eric L Kilpatrick1, Prakash Narayan, Robert M Mentzer, Robert D Lasley.   

Abstract

Adenosine A2a receptors are found in coronary vascular tissue although, their presence in myocardium is subject to investigation. Although there have been numerous studies on adenosine A2a receptor agonist effects on contractility and cAMP levels in ventricular myocytes, these have yielded conflicting results. Negative pharmacological studies have even led to the conclusion that A2a receptors are not present in cardiac myocytes. The purpose of this study was to determine whether A2a receptors are expressed in rat ventricular myocytes and what physiological effects are mediated via activation of these receptors. Western blot analysis with a polyclonal antibody raised against a peptide sequence specific to the carboxy terminus of the A2a receptor revealed the presence of a band at approximately 45 kDa. However, the immunoreactivity was located in the nonmembrane fraction of the cell lysate. The membrane fraction only exhibited an immunoreactive band > or = 50 kDa. Treatment of isolated myocytes with the adenosine A2a agonist 2-[4-[(2-carboxyethyl)-phenyl]ethylamino]-5'-N-ethylcarboxamidoadenosine (CGS-21680) exerted no effects on cAMP levels or myocyte twitch amplitude. These results indicate that although rat ventricular myocytes appear to express adenosine A2a receptors, stimulation with an A2a agonist exerts no functional effects, possibly because of the subcellular localization of the A2a receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834501     DOI: 10.1152/ajpheart.00808.2001

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

1.  Differential effects of adenosine A2a and A2b receptors on cardiac contractility.

Authors:  P Charukeshi Chandrasekera; Victoria J McIntosh; Frank X Cao; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-08       Impact factor: 4.733

2.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

3.  Cardiac-restricted overexpression of the A(2A)-adenosine receptor in FVB mice transiently increases contractile performance and rescues the heart failure phenotype in mice overexpressing the A(1)-adenosine receptor.

Authors:  Tung O Chan; Hajime Funakoshi; Jianliang Song; Xue-Qian Zhang; JuFang Wang; Paul H Chung; Brent R DeGeorge; Xue Li; Jin Zhang; David E Herrmann; Maura Diamond; Eman Hamad; Steven R Houser; Walter J Koch; Joseph Y Cheung; Arthur M Feldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

Review 4.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.

Authors:  Enbo Zhan; Victoria J McIntosh; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-08       Impact factor: 4.733

Review 6.  Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression.

Authors:  Martha de Oliveira Bravo; Juliana Lott Carvalho; Felipe Saldanha-Araujo
Journal:  Purinergic Signal       Date:  2016-08-25       Impact factor: 3.765

7.  Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1/A2A receptor agonist, on native IKr and cloned HERG current.

Authors:  Noriko Saegusa; Toshiaki Sato; Takehiko Ogura; Issei Komuro; Haruaki Nakaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-19       Impact factor: 3.000

8.  Contractile effects of adenosine, coronary flow and perfusion pressure in murine myocardium.

Authors:  Laura Willems; John P Headrick
Journal:  Pflugers Arch       Date:  2006-10-28       Impact factor: 3.657

9.  ATL 313, A Selective A(2A) Adenosine Receptor Agonist, Reduces Myocardial Infarct Size in a Rat Ischemia/Reperfusion Model.

Authors:  Wangde Dai; Sharon L Hale; Rohith Nayak; Robert A Kloner
Journal:  Open Cardiovasc Med J       Date:  2009-11-25

10.  Asystole following regadenoson infusion in stable outpatients.

Authors:  Jeffrey Rosenblatt; Deirdre Mooney; Timothy Dunn; Mylan Cohen
Journal:  J Nucl Cardiol       Date:  2014-05-31       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.